Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer

Journal of the National Cancer Institute

Volumn 103, Issue 8, 2011, Pages 628-635

  Tricoli, James V ^a,b   Seibel, Nita L ^a   Blair, Donald G ^b   Albritton, Karen ^c   Hayes Lattin, Brandon ^d  

^a Division of Cancer Treatment and Diagnosis   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CORTICOSTEROID; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENCE; ADULT; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; COLON CANCER; FAMILIAL POLYPOSIS; HUMAN; INFORMATION PROCESSING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UNITED STATES; WORKSHOP;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; BREAST NEOPLASMS; COLONIC NEOPLASMS; DATA INTERPRETATION, STATISTICAL; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISPANIC AMERICANS; HUMANS; MALE; MUTATION; NEOPLASM STAGING; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK FACTORS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79955454010     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr094     Document Type: Review

References (51)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-1043. (Pubitemid 351389536)
2. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 2009;144(2):147-156.
3. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2009;106(23):9414-9418.
4. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-480.
5. Kang H, Chen IM, Wilson CS, et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 2010;115(7):1394-1405.
6. Harvey RC WX, Dobbin KK, Davidson GS, et al. Identification of novel cluster groups in pediatric high risk B-precursor acute lymphoblastic leukemia by gene expression profiling: correlation with genome-wide DNA copy number alterations clinical characteristics and outcome. Blood. 2010;116(23):4874-4884.
7. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115(26):5312-5321.
8. Harrison CJ, Martineau M, Secker-Walker LM. The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute lymphoblastic leukaemia: a valuable resource for patient management. Br J Haematol. 2001;113(1):3-10. (Pubitemid 32423294)
9. Harris RL, Harrison CJ, Martineau M, et al. Is trisomy 5 a distinct cytogenetic subgroup in acute lymphoblastic leukemia? Cancer Genet Cytogenet. 2004;148(2):159-162. (Pubitemid 38087964)
10. Harewood L, Robinson H, Harris R, et al. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia. 2003;17(3):547-553. (Pubitemid 36395648)
11. Moorman AV, Richards SM, Robinson HM, et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood. 2007;109(6):2327-2330. (Pubitemid 46425871)
12. Akasaka T, Balasas T, Russell LJ, et al. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood. 2007;109(8):3451-3461. (Pubitemid 46572535)
13. Russell LJ, Akasaka T, Majid A, et al. t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood. 2008;111(1):387-391.
14. Russell LJ, De Castro DG, Griffiths M, et al. A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin. Leukemia. 2009;23(3):614-617.
15. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688-2698.
16. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112(5):1646-1654.
17. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21(5):774-780. (Pubitemid 46606434)
18. de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18(12):2032-2035. (Pubitemid 40028431)
19. Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer. 2007;48(3):254-261. (Pubitemid 46238513)
20. Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007;25(7):813-819. (Pubitemid 350002881)
21. Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol. 2008;66(1):65-74. (Pubitemid 351324129)
22. Yau C, Fedele V, Roydasgupta R, et al. Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Res. 2007;9(5):R59.
23. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003;95(22):1692-1702. (Pubitemid 37509078)
24. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol. 2009;36(3):237-249.
25. Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324-3330.
26. Anders CK, Acharya CR, Hsu DS, et al. Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PloS One. 2008;3(1):e1373.
27. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109(1):123-139. (Pubitemid 351538762)
28. Gapstur SM, Dupuis J, Gann P, et al. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer. 1996;77(8):1465-1471.
29. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502. (Pubitemid 43854964)
30. Ambrosone CB, Ciupak GL, Bandera EV, et al. Conducting molecular epidemiological research in the age of HIPAA: a multi-institutional case-control study of breast cancer in African-American and European-American women. J Oncol. 2009;2009:871250.
31. Kuperwasser C, Chavarria T, Wu M, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA. 2004;101(14):4966-4971. (Pubitemid 38469186)
32. Proia DA, Kuperwasser C. Reconstruction of human mammary tissues in a mouse model. Nat Protoc. 2006;1(1):206-214.
33. Wu M, Jung L, Cooper AB, et al. Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. Proc Natl Acad Sci USA. 2009;106(17):7022-7027.
34. Gupta PB, Proia D, Cingoz O, et al. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res. 2007;67(5):2062-2071. (Pubitemid 46424224)
35. Bleyer A, Barr R, Hayes-Lattin B, et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008;8(4):288-298. (Pubitemid 351430865)
36. Hill DA, Furman WL, Billups CA, et al. Colorectal carcinoma in childhood and adolescence: a clinicopathologic review. J Clin Oncol. 2007;25(36):5808- 5814.
37. Liang JT, Huang KC, Cheng AL, et al. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. Br J Surg. 2003;90(2):205-214. (Pubitemid 36237896)
38. Liu B, Farrington SM, Petersen GM, et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med. 1995;1(4):348-352.
39. Kakar S, Aksoy S, Burgart LJ, et al. Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol. 2004;17(6):696-700. (Pubitemid 38715493)
40. Durno C, Aronson M, Bapat B, Cohen Z, Gallinger S. Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma. Gut. 2005;54(8):1146-1150. (Pubitemid 41025910)
41. Sultan I, Rodriguez-Galindo C, El-Taani H, et al. Distinct features of colorectal cancer in children and adolescents: a population-based study of 159 cases. Cancer. 2010;116(3):758-765.
42. Lynch HT, Lynch JF, Lynch PM, Attard T. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Fam Cancer. 2008;7(1):27-39.
43. Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet. 2008;124(2):105-122.
44. Engle SJ, Hoying JB, Boivin GP, et al. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res. 1999;59(14):3379-3386. (Pubitemid 29334496)
45. Simon R, Korn EL, McShane LM, Radmacher MD, Wright GW, Zhao Y. Design and Analysis of DNA. Microarray Investigations. New York, NY: Springer-Verlag; 2004.
46. Simon R. Interpretation of genomic data: questions and answers. Semin Hematol. 2008;45(3):196-204. (Pubitemid 351876122)
47. Rubinstein LV. Therapeutic studies. Hematol Oncol Clin North Am. 2000;14(4):849-876. ix. (Pubitemid 30636690)
48. Green S, Benedetti J, Crowley J. Clinical Trials in Oncology. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC Press; 2003.
49. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res. 2009;15(6):1898-1905.
50. Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol. 2005;23(28):7199-7206.
51. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR, eds. Introduction to Meta-Analysis. West Sussex, UK: John Wiley & Sons; 2009.